DIFFUSE LARGE B-CELL LYMPHOMA

This early-phase trial tested a combination of two drugs, tazemetostat and venetoclax, in people with Non-Hodgkin lymphoma that had come back or stopped responding to treatment. The main goals were to find the safest dose and understand side effects. Only 3 people took part befor…

This early-phase study tested a new experimental drug, PF-08046032, alone or combined with another drug (sasanlimab) in 6 adults with advanced lymphomas or solid tumors that had spread or stopped responding to standard treatments. The main goals were to check safety and find the …

This study looked at people with blood cancers receiving a stem cell transplant from an unrelated donor. The goal was to find which of two drug combinations (cyclosporine and sirolimus with either MMF or post-transplant cyclophosphamide) better prevents a serious side effect call…

This study tested an experimental drug called SAR444245, alone or with pembrolizumab, in 14 people aged 12 and older with B cell lymphoma that returned or didn't respond to prior treatments. The goal was to see if the drug could shrink tumors. The trial was terminated early, so r…

This study looked at using umbilical cord blood transplants after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. It included 200 people and aimed to see how many survived one year after the transplant. The approach is intense and mean…

This study tested a new mix of cancer drugs (PV-RGDP) for people with diffuse large B-cell lymphoma that came back or didn't get better after first treatment. The goal was to see if adding polatuzumab vedotin to standard chemo could improve response. Only 5 people took part befor…

This study looked at a combination of three medicines (maplirpacept, tafasitamab, and lenalidomide) for people with diffuse large B-cell lymphoma that had come back or didn't respond to prior treatment. Participants were not able or willing to have a stem cell transplant or CAR-T…

This study tested a combination of two experimental drugs (maplirpacept and glofitamab) for people with a type of blood cancer called diffuse large B-cell lymphoma that had come back or not responded to prior treatments. Participants had already tried at least two other treatment…

This study tested the drug pembrolizumab in people with a fast-growing lymphoma (DLBCL) that had come back or not responded to other treatments. Only patients whose cancer had a specific genetic change in PD-L1 were included. The study was stopped early after enrolling just 5 par…